Hyperphosphatemia Related to Chronic Kidney Disease Clinical Trial
Official title:
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).
| Status | Recruiting |
| Enrollment | 45 |
| Est. completion date | June 2025 |
| Est. primary completion date | January 2025 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 6 Years to 16 Years |
| Eligibility | Inclusion Criteria: - Age 6 years to <17 years at Screening. - Weight = 20 kilograms (kg) (dry weight for dialysis participants) at Screening. - Chronic kidney disease (CKD) requiring chronic dialysis (i.e., hemodialysis or peritoneal dialysis), or CKD not on dialysis with an estimated glomerular filtration rate (eGFR) <30 milliliters per minute (mL/min)/1.73 meters squared (m^2) at Screening. - Documented history of CKD-related hyperphosphatemia for at least 3 months prior to the screening visit. - If participant is or is not on phosphate binder(s) at Visit 1, serum phosphorus must be: - 6 to <13 years: >5.8 milligrams per deciliter (mg/dL). - 13 to <17 years: >4.5 mg/dL. - If participant is on phosphate binder(s) at Visit 1, and serum phosphorus is not greater than the above stated age-limit criteria, approximately 1 to 4-weeks of washout period is required and at Visit 1a or Visit 1b, serum phosphorus must be greater than the age above stated age-limit criteria. - Transferrin saturation (TSAT) <50%. - Parent/legal guardian must be willing and able to give written informed consent, and child (participant) willing and able to give age-appropriate assent according to local regulatory requirements. - Female participants of childbearing potential, defined as post menarche and not surgically sterile, must have a negative serum pregnancy test. - Dialysis adequacy stable on current mode of dialysis prior to screening and agree to maintain dialysis prescription for the duration of the pharmacodynamic assessment period unless changes are needed for safety. A minimum dialysis adequacy (dialysis clearance of urea-dialysis time/volume of distribution of urea [Kt/V]), defined by the following: 1. Hemodialysis adequacy: single-pool Kt/V =1.2 for at least 1 hemodialysis session within 2 months. 2. Peritoneal dialysis: At least 1Kt/V reading =1.8 within 4 months. Exclusion Criteria: - Active significant GI disorder, including overt GI bleeding or active inflammatory bowel disease. - Liver transaminases (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) >3× the upper limit of normal at Screening. - Unable to swallow pills, if participant requires tube feeding, ferric citrate must be taken orally and not administered via feeding tube. - Non-renal cause of hyperphosphatemia. - Active drug or alcohol dependence or abuse (excluding tobacco use or medicinal marijuana) within the 12 months prior to Screening or evidence of such abuse (in the opinion of the Investigator). - Malignancy, except for participants who have been disease-free for at least 2 years after curative therapy. - Participants with a functioning organ transplant. - A known allergy or intolerance to ferric citrate or any of its constituents. - Participants who do not agree to remain abstinent or assent to use a combination of 2 of the following highly effective birth control methods for at least 28 days before the first dose, during the study (including during dose interruptions), and for at least 30 days after the last dose: - Barrier method of contraception: condoms (female or male) with or without a spermicidal agent, diaphragm, or cervical cap with spermicide. - Intrauterine device (IUD). - Hormone-based contraceptives which are associated with inhibition of ovulation. - Females who are pregnant or breast-feeding other children. Participants who are being breastfed are eligible to participate in this study. - Any other medical condition that, in the opinion of the Investigator, renders the participant unable to or unlikely to complete the trial or that would interfere with optimal participation in the trial or produce significant risk to the participant. - The participant, in the opinion of the Investigator, is unable to adhere to the requirements of the study. - Receipt of any investigational drug within 4 weeks before Screening. - History of hemochromatosis or iron overload syndrome (e.g, hereditary sideroblastic anemia, thalassemia). |
| Country | Name | City | State |
|---|---|---|---|
| United States | University of New Mexico | Albuquerque | New Mexico |
| United States | Children's Hospital Colorado | Aurora | Colorado |
| United States | Johns Hopkins Hospital | Baltimore | Maryland |
| United States | University of Alabama at Birmingham (UAB) - Children's of Alabama | Birmingham | Alabama |
| United States | Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio |
| United States | Children's Mercy Hospital - Kansas City | Kansas City | Missouri |
| United States | University of Minnesota | Minneapolis | Minnesota |
| United States | Phoenix Childrens Hospital | Phoenix | Arizona |
| United States | University of Utah | Salt Lake City | Utah |
| United States | University of California, San Francisco (UCSF) - Department of Nephrology | San Francisco | California |
| United States | Seattle Children's Hospital | Seattle | Washington |
| United States | Stanford University Medical Center | Stanford | California |
| United States | University of South Florida | Tampa | Florida |
| Lead Sponsor | Collaborator |
|---|---|
| Keryx Biopharmaceuticals |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of participants with serious and non-serious treatment-emergent adverse events (TEAEs) including gastrointestinal (GI) AEs of special interest | up to Week 40 | ||
| Primary | Number of participants with clinically significant laboratory abnormalities or changes in laboratory results | up to Week 40 | ||
| Primary | Number of participants with TEAEs leading to the discontinuation of ferric citrate | up to Week 40 | ||
| Secondary | Change from baseline in serum phosphorus to Week 12/early termination (ET) | Baseline; up to Week 12 |